ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511711-21-00

Enrollment

Registered

2024-06-12

Start date

2024-12-16

Completion date

Unknown

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III non-small cell lung cancer

Brief summary

Safety defined as the rates of severe surgical morbidity and mortality (Clavien-Dindo grade 3-5) and the percentage of patients with treatment-related adverse events (Gr III-V) within 90-days of surgery, Number of patients able to proceed to durvalumab consolidation after surgery

Detailed description

Rate of complete surgical resection (R0), DFS in 2 years, defined from the day of surgery

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety defined as the rates of severe surgical morbidity and mortality (Clavien-Dindo grade 3-5) and the percentage of patients with treatment-related adverse events (Gr III-V) within 90-days of surgery, Number of patients able to proceed to durvalumab consolidation after surgery	—

Secondary

Measure	Time frame
Rate of complete surgical resection (R0), DFS in 2 years, defined from the day of surgery	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026